Trial Profile
A Phase 2 study of once-a-day triplet regimen of PTI-428, PTI-808 and PTI-801
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 13 Jun 2018
Price :
$35
*
At a glance
- Drugs Dirocaftor (Primary) ; Nesolicaftor (Primary) ; Posenacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Therapeutic Use
- 13 Jun 2018 New trial record
- 06 Jun 2018 According to Proteostasis Therapeutics media release, the company plans to initiate this trial by the end of the current quarter and results are expected later this year.